News for Hoth Therapeutics, Inc. (HOTH)

On July 23, 2025, D. Boral Capital, led by analyst Jason Kolbert, reaffirmed its "Buy" rating for Hoth Therapeutics (HOTH). The investment firm maintained its p

PR NewswireNEW YORK, July 22, 2025 NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, to

Hoth Therapeutics (HOTH) has initiated a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs and the Foundation

PR NewswireNEW YORK, June 23, 2025 Developed to address EGFR inhibitor-induced skin toxicities in cancer patientsNEW YORK, June 23, 2025 /PRNewswire/ -- H

Hoth Therapeutics (HOTH) is hosting a virtual KOL event spotlighting their HT-001 therapy on June 24, 2025. The event will present interim results from

PR NewswireNEW YORK, June 18, 2025 NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical compa

Hoth Therapeutics (HOTH) successfully regains Nasdaq compliance by maintaining a stock price above $1.00 for 10 consecutive trading sessions. CEO Robb K

PR NewswireNEW YORK, June 18, 2025 HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT ”” Dose-Dependent Activity, No Toxici

Hoth Therapeutics (HOTH) revealed promising results from preclinical trials involving HT-KIT, an experimental treatment designed to target the c-KIT pathway in

Hoth Therapeutics (HOTH) reports positive preclinical safety data for HT-KIT with dose-dependent liver activity and no observed toxicity. Key study find

PR NewswireNEW YORK, April 17, 2025 Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers f

PR NewswireNEW YORK, March 10, 2025 HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epi

PR NewswireNEW YORK, March 4, 2025 Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy ExpenditureHo

PR NewswireNEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a

PR NewswireNEW YORK, Jan. 21, 2025 IP will be used to pursue further indications for HT-001 Cancer TherapeuticNEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.42%

U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.11% to 42,658.41 while the NAS...

U.S. stocks traded higher this morning, with the Dow Jones index jumping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded ...